全文获取类型
收费全文 | 32365篇 |
免费 | 1712篇 |
国内免费 | 98篇 |
专业分类
耳鼻咽喉 | 438篇 |
儿科学 | 2298篇 |
妇产科学 | 684篇 |
基础医学 | 3626篇 |
口腔科学 | 597篇 |
临床医学 | 1893篇 |
内科学 | 6589篇 |
皮肤病学 | 1088篇 |
神经病学 | 1596篇 |
特种医学 | 1226篇 |
外科学 | 4936篇 |
综合类 | 1033篇 |
一般理论 | 15篇 |
预防医学 | 1590篇 |
眼科学 | 1576篇 |
药学 | 2568篇 |
中国医学 | 159篇 |
肿瘤学 | 2263篇 |
出版年
2023年 | 189篇 |
2022年 | 474篇 |
2021年 | 929篇 |
2020年 | 541篇 |
2019年 | 621篇 |
2018年 | 870篇 |
2017年 | 579篇 |
2016年 | 834篇 |
2015年 | 778篇 |
2014年 | 1211篇 |
2013年 | 1414篇 |
2012年 | 2114篇 |
2011年 | 2243篇 |
2010年 | 1212篇 |
2009年 | 987篇 |
2008年 | 1683篇 |
2007年 | 1824篇 |
2006年 | 1603篇 |
2005年 | 1495篇 |
2004年 | 1364篇 |
2003年 | 1228篇 |
2002年 | 1109篇 |
2001年 | 764篇 |
2000年 | 709篇 |
1999年 | 637篇 |
1998年 | 291篇 |
1997年 | 211篇 |
1996年 | 166篇 |
1995年 | 161篇 |
1994年 | 137篇 |
1993年 | 140篇 |
1992年 | 360篇 |
1991年 | 397篇 |
1990年 | 346篇 |
1989年 | 364篇 |
1988年 | 311篇 |
1987年 | 280篇 |
1986年 | 268篇 |
1985年 | 279篇 |
1984年 | 220篇 |
1983年 | 183篇 |
1979年 | 241篇 |
1978年 | 158篇 |
1977年 | 148篇 |
1976年 | 135篇 |
1975年 | 165篇 |
1974年 | 155篇 |
1973年 | 176篇 |
1972年 | 138篇 |
1971年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
Maurizio Fava Michael E Thase Charles DeBattista Karl Doghramji Sanjay Arora Rod J Hughes 《Annals of clinical psychiatry》2007,19(3):153-159
BACKGROUND: Partial response, no response, or residual symptoms following antidepressant therapy is common in clinical psychiatry. This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue. METHODS: This retrospective analysis pooled the data of patients (18-65 yrs) who participated in two randomized, double-blind, placebo-controlled studies of modafinil (6-week, flexible-dose study of 100-400 mg/day or 8-week, fixed-dose study of 200 mg/day) plus SSRI therapy. Patients (n=348) met criteria for several residual symptoms (Epworth Sleepiness Scale [ESS] score>or=10; 17-item Hamilton Depression Scale [HAM-D] score between 4 and 25; and Fatigue Severity Scale [FSS] score>or=4). RESULTS: Compared to placebo, modafinil augmentation rapidly (within 1 week) and significantly improved overall clinical condition (Clinical Global Impression-Improvement), wakefulness (ESS), depressive symptoms (17-item HAM-D), and fatigue (FSS) (p<.01 for all). At final visit, patients receiving modafinil augmentation experienced statistically significant improvements in overall clinical condition, wakefulness, and depressive symptoms. Modafinil was well tolerated in combination with SSRI. CONCLUSIONS: Results of this pooled analysis provide further evidence suggesting that modafinil is an effective and well-tolerated augmentation therapy for partial responders to SSRI therapy, particularly when patients continue to experience fatigue and excessive sleepiness. 相似文献
112.
113.
To identify the role of protein kinase C (PKC) isoforms in multidrug resistance in tumor cells, we examined the PKC isoform pattern in the multidrug resistant P388/ADR cell line and studied the effect of down regulation of PKC isoforms on intracellular daunorubicin accumulation and P-glycoprotein expression. Using monoclonal antibodies to PKC alpha, beta and gamma and flow cytometry technique we showed that P388/ADR cells overexpressed PKC alpha and beta as compared to drug sensitive P388 cells. Prolonged treatment of P388/ADR cells with phorbol myristate acetate (PMA), a procedure that is known to down regulate PKC, resulted in the down regulation of total PKC activity and the PKC beta isoform (at the protein level) that was accompanied by the correction of daunorubicin accumulation in P388/ADR cells. The level of expression of P-glycoprotein in PMA treated cells was similar to that of untreated cells. These results suggest that PKC beta regulates the drug efflux function of P-glycoprotein. 相似文献
114.
P. Arora V. Kher P. K. Rai M. K. Singhal S. Gulati A. Gupta 《Pediatric nephrology (Berlin, Germany)》1997,11(2):153-155
Various factors were analyzed in 80 consecutive children under 16 years who had acute renal failure (ARF), for various prognostic
factors. Overall mortality was 42.5%, with significantly higher levels seen in hemolytic uremic syndrome (68%, P <0.05) and associated with cardiac surgery (90.9%, P <0.01). Anuria (67.6% vs. 43.5%, P <0.05), need for dialysis (85.3% vs. 56.5%, P <0.05), neurological complications (50% vs. 6.3%, P <0.01), and respiratory complications (35.2% vs. 2.1%, P <0.01) were significantly higher in nonsurvivors than survivors. Multiple regression analysis showed the presence of neurological
and respiratory complications to be poor prognostic factors.
Received May 2, 1995; received in revised form August 28, 1996; accepted September 13, 1996 相似文献
115.
116.
117.
Dr. S. K. Gupta J. C. Ritchie E. H. Ellinwood K. Wiedemann F. Holsboer 《European journal of clinical pharmacology》1992,43(1):51-55
Summary Changes in time course effected by cortisol suppression and the relationship of these changes to the plasma dexamethasone concentration of suppressor and non-suppressor patients are described in this report on a combined pharmacokinetic-pharmacodynamic model.Thirteen depressed patients (8 suppressors and 5 non-suppressors) received an intravenous dose (1.5 mg) of dexamethasone. The drug-induced effect changes are found to lag behind, in time, the plasma drug level changes. To accurately relate the temporal relationship of effect changes to plasma dexamethasone levels, a pharmacodynamic model (sigmoid-Emax) was combined with a pharmacokinetic model that incorporated an effect compartment. The magnitude of the time-lag was quantified by the half-time of equilibration between concentrations in the hypothetical effect compartment and the plasma dexamethasone levels (t&frac;keo).The t&frac;keo of the nonsuppressing group was about 50 of that of the suppressing group, indicating that for a given plasma level the onset and termination of effect for the nonsuppressing group is about two times more rapid than for the suppressing group. Moreover, the model can estimate the effect-site concentration that causes one-half of the maximal predicted effect (EC50), a measure of an individual's sensitivity to dexamethasone. The receptor sensitivity (as determined from the EC50 ratio) of the suppressing group was about twice that of the nonsuppressing group. 相似文献
118.
E B Savage S W Downing M B Ratcliffe M Fallert K B Gupta G S Tyson D K Bogen L H Edmunds 《The Journal of thoracic and cardiovascular surgery》1992,104(3):752-762
Anteroapical left ventricular aneurysms were produced in 23 sheep by coronary arterial ligation. Plication of the aneurysm does not change stroke volume or cardiac output and does not significantly change left ventricular oxygen consumption from the preoperative value of 5.1 +/- 2.6 ml/100 gm per minute. Plication, however, does increase left ventricular end-systolic elastance from 3.2 +/- 0.9 to 4.4 +/- 1.5 mm Hg/mm (p = 0.005). In nine of these sheep the midsagittal plane of the left ventricle was imaged by means of an array of sonomicrometry crystals before and after plication of the aneurysm. Regional wall stresses at end-systole and end-diastole and changes in diastolic function were calculated for anterior and posterior ventricular walls in the border zone adjacent to the aneurysm and in more basilar myocardium remote from the infarct. Plication significantly reduced end-systolic wall stresses and systolic stress integrals in the posterior border zone and remote myocardium, but it did not significantly change anterior wall systolic stresses or stress integrals. Plication also decreased diastolic stretching of border zone myocardium. Plication of anteroapical left ventricular aneurysm produced a shorter, more spherical ventricle and removed the dyskinetic segments but altered deformation (strain) in both circumferential and longitudinal directions. The changes in ventricular wall geometry and deformation provide an explanation for the increased ventricular end-systolic elastance and unchanged stroke volume observed after aneurysm plication. 相似文献
119.
120.